RPG
VRTX icon

Risk Paradigm Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Risk Paradigm Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-127
Closed -$10.9K – 267
2016
Q2 		$10.9K Hold
127
– – 0.01% 221
2016
Q1 		$10.1K Hold
127
– – 0.01% 220
2015
Q4 		$16K Hold
127
– – 0.02% 192
2015
Q3 		$13.2K Buy
+127
New +$16.3K 0.03% 188

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Risk Paradigm Group's VRTX Position: Q3 2016 in Review

Risk Paradigm Group sold out of Vertex Pharmaceuticals (VRTX) in Q3 2016, closing a stake of 127 shares — an estimated $10.9K sold.

Risk Paradigm Group first reported a position in VRTX in Q3 2015 and held it in 4 quarters. The position peaked at $16K in Q4 2015. 491 funds tracked by Wall St. Rank hold VRTX as of Q3 2016.

  • Risk Paradigm Group reported no remaining Vertex Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Risk Paradigm Group sold 127 Vertex Pharmaceuticals shares in Q3 2016, an estimated $10.9K.
  • Risk Paradigm Group first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 4 quarters.
  • Risk Paradigm Group's Vertex Pharmaceuticals position peaked at $16K in Q4 2015.
  • 491 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2016.

Based on Risk Paradigm Group's 13F filing for Q3 2016, filed 14 Nov 2016.